Akeso (HKSE:09926) Gross-Profit-to-Asset % : 17.44% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Akeso Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Akeso's annualized Gross Profit for the quarter that ended in Dec. 2023 was HK$1,735 Mil. Akeso's average Total Assets over the quarter that ended in Dec. 2023 was HK$9,949 Mil. Therefore, Akeso's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 17.44%.

Akeso Gross-Profit-to-Asset % Historical Data

The historical data trend for Akeso's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akeso Gross-Profit-to-Asset % Chart

Akeso Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

6.06

4.55

13.81

59.40

Akeso Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial						2.76	5.40	22.69	98.48	17.44

Competitive Comparison of Akeso's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Akeso's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akeso's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akeso's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Akeso's Gross-Profit-to-Asset % falls into.

Akeso Gross-Profit-to-Asset % Calculation

Akeso's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	4804.976	/	( (6137.406	+	10042.082)	/ 2 )
	=	4804.976	/	8089.744
	=	59.40 %

Akeso's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	1735.446	/	( (9855.057	+	10042.082)	/ 2 )
	=	1735.446	/	9948.5695
	=	17.44 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Akeso Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Akeso's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Akeso (HKSE:09926) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (HKSE:09926) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

AKESF:USA 4RY:Germany

Address

6 Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437

Website

https://www.akesobio.com

Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.

Executives

Xia Yu	2501 Other
Wang Zhongmin Maxwell	2501 Other
Li Baiyong	2501 Other
Green Court Capital Holdings Limited	2201 Interest of corporation controlled by you
Green Court Capital Management Limited	2102 Investment manager
Green Court Management Holdings Llc	2201 Interest of corporation controlled by you
Yao Yulin	2201 Interest of corporation controlled by you
Shenzhen Capital Group Co., Ltd.	2201 Interest of corporation controlled by you
Xia Yu	2501 Other
Shen Zhen Shi Chuang Xin Tou Zi Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Zheng Xun
Zhong Shan Shi Xun Xiang Gu Quan Tou Zi Guan Li Qi Ye You Xian He Huo
Cantrust (far East) Limited	2301 Trustee
Aquae Hyperion Limited	2101 Beneficial owner
Htkf Investments Limited	2101 Beneficial owner

Akeso (HKSE:09926) Headlines

No Headlines